Lucetam, 200 mg/ml 5 ml 10 pcs

Lucetam has a nootropic effect.

The active ingredient in Lucetam is piracetam, a cyclic derivative of gamma-aminobutyric acid (GABA), a nootropic. Directly affects the brain, improves cognitive (learning) processes such as learning ability, memory, attention, memorization ability, as well as increases mental performance, without the development of sedative and psychostimulant effect. It affects the central nervous system in different ways: it changes the speed of excitation distribution in the brain, improves neuronal plasticity and metabolic processes in nerve cells. It improves interaction between cerebral hemispheres and synaptic conduction in neocortical structures, increases mental performance, improves cerebral blood flow.

Lucetam improves microcirculation in the brain, affecting the rheological characteristics of the blood and does not cause vasodilatation.

Lucetam inhibits platelet aggregation and restores the elasticity of the erythrocyte membrane and the ability of the latter to pass through the microcirculatory channel. Reduces erythrocyte adhesion. In dose 9.6 g it decreases the level of fibrinogen and Willebrand factor by 30% – 40% and prolongs bleeding time.

Lucetam has a protective and restorative effect on impaired brain function due to hypoxia, intoxication or trauma. Lucetam reduces the severity and duration of vestibular nystagmus.

Pharmacokinetics

The elimination half-life of piracetam from blood plasma is 4-5 hours and 8.5 hours from cerebrospinal fluid. Period of semi-elimination is prolonged in renal insufficiency. Pharmacokinetics of piracetam does not change in patients with hepatic insufficiency.

Piracetam penetrates through the blood-brain and placental barrier and membranes used in hemodialysis. Piracetam selectively accumulates in the tissues of the cerebral cortex, mainly in the frontal, parietal and occipital lobes, in the cerebellum and basal nuclei. Piracetam does not bind to blood plasma proteins, is not metabolized in the body and 80-100% of piracetam is excreted unchanged by the kidneys through renal filtration. Renal clearance of piracetam in healthy volunteers is 86 ml/min.

Indications

Symptomatic treatment of psycho-organic syndrome, particularly in elderly patients suffering from decreased memory, concentration and general activity, dizziness, mood changes, behavior disorders, gait disturbances, and in patients with Alzheimer’s disease and senile dementia of the Alzheimer type.

Treatment of ischemic stroke sequelae, such as speech disorders, emotional disturbances, motor and mental activity disorders.

Chronic alcoholism – for the treatment of psychoorganic and withdrawal syndromes.

During recovery from trauma and intoxication of the brain.

The treatment of vertigo and related balance disorders, except for vertigo of mental origin.

As part of the complex therapy of learning disabilities in children, especially in cases of difficulty in acquiring specific reading, writing, and counting skills that cannot be explained by mental retardation, inadequate instruction, or peculiarities of the family environment.

For the treatment of cortical myoclonias as mono- or complex therapy.

Active ingredient

Composition

Active substance:

piracetam;

Auxiliary substances:

Sodium acetate trihydrate, 5/15 mg;

ice-cold acetic acid – up to pH 5.8;

water for injection – up to 5/15 ml

How to take, the dosage

Intravenously. The daily dose is 30-160 mg/kg (3-12 g/day), the frequency of administration is 2-4 times a day. Parenteral administration of piracetam is prescribed when oral forms of the drug cannot be used, for example, when swallowing is difficult, or when the patient is in a coma.

Lucetam solution is compatible with the following infusion solutions:

– Glucose 5, 10, 20%;

– Fructose 5, 10, 20%;

– Levulose 5%;

– Sodium chloride 0.9%;

– Dextran 40 10% in 0.9% sodium chloride solution;

– Dextran 100 6% in 0.9% sodium chloride solution;

– Ringer’s solution;

– Mannitol-Dextran;

– Hydroxyethyl starch 6%.

The infusion solutions with the addition of piracetam are stable for at least 24 hours.

Adults. Symptomatic treatment of psychorganic syndrome: in symptomatic treatment of chronic psychorganic syndrome, depending on the severity of symptoms 2.4-4.8 g/day is prescribed, distributed in 2-3 injections.

The treatment of vertigo and related balance disorders: 2.4-4.8 g/day, spread over 2-3 injections.

Cortical myoclonias: treatment begins with 7.2 g/day, every 3-4 days the dose is increased by 4.8 g/day until a maximum dose of 24 g/day is reached. Thereafter the patient is switched to oral form of Lucetam. Treatment is continued throughout the entire period of the disease. To prevent deterioration of patients’ condition the drug should not be discontinued abruptly. It is necessary to reduce doses of the drug gradually. If there is no effect or there is a slight therapeutic effect, treatment shall be discontinued.

Cure (parenterally) of sickle cell vasoconstriction crisis: The drug is used in a dose of 300 mg/kg divided into 4 doses.

Children and adolescents

In the complex therapy of dyslexia in children aged 8 years and older: the daily dose is 3.2 g divided into 2 doses.

Curing sickle cell vasoconstriction crisis in children over 3 years of age: 300 mg/kg, divided into 4 doses.

Dosing in patients with impaired renal function: Because piracetam is excreted by the kidneys, caution should be exercised when treating patients with renal insufficiency in accordance with the dosage regimen given.

The calculation of the dose should be based on an assessment of the patient’s creatinine clearance and the table of recommendations for the treatment of patients, depending on the severity of renal failure, see above.

Dosing in elderly patients. In elderly patients, the dose is adjusted in the presence of renal insufficiency and renal function monitoring is necessary during long-term therapy.

Dosing in patients with liver dysfunction. Patients with impaired liver function do not require dose adjustment.

Contraindications

Side effects

Nervous system disorders: hyperkinesias, irritability, somnolence, depression, asthenia: these symptoms occur more frequently in elderly patients receiving doses over 2.4 g/day, in most cases it is possible to achieve regression of such symptoms by reducing the drug dose. Headache, dizziness, insomnia, mental agitation, restlessness, balance disorders, tremor, ataxia, worsening of epilepsy, anxiety, hallucinations, confusion, increased libido.

Blood and lymphatic disorders: bleeding

Immune system disorders: hypersensitivity, including anaphylaxis

Hearing and labyrinth disorders: Dizziness (vertigo)

Cardiovascular system disorders: decreased or increased blood pressure.

Digestive system disorders: nausea, vomiting, diarrhea, abdominal pain, epigastric pain.

Metabolic and nutrition disorders: weight gain.

Skin disorders: dermatitis, itching, urticaria.

Allergic reactions: angioedema.

General disorders and disorders at the injection site: pain at the injection site, thrombophlebitis, hyperthermia.

Similarities